Prostate
ARASENS
A randomized, double·blind, placebo·controlled Phase III study of ODM·201 versus placebo in addition to standard androgen deprivation therapy and docetaxel in patients with metastatic hormone·sensitive prostate cancer.
Paris
PHILIPPE BEUZEBOC
Prostate
CARD (LPS14201)
A Randomized, Open Label, Multicenter Study of Cabazitaxel Versus an Androgen Receptor (AR)-Targeted Agent (Abiraterone or Enzalutamide) in mCRPC Patients Previously Treated With Docetaxel and Who Rapidly Failed a Prior AR-targeted Agent (CARD).
Paris
PHILIPPE BEUZEBOC
Appareil pulmonaire
CheckMate 384 (CA209-384)
A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects With Advanced or Metastatic Non-small Cell Lung Cancer Who Received up to 12 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks
Paris
CATHERINE DANIEL
Prostate
MK3475-365
Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-365)
Paris
EMANUELA ROMANO
Appareil pulmonaire
LUNG-ART
Phase III Study Comparing Post-Operative Conformal Radiotherapy to No Post-Operative Radiotherapy in Patients With Completely Resected Non-Small Cell Lung Cancer and Mediastinal N2 Involvement
Paris, Saint-Cloud
SYLVIE HELFRE, PATRICIA MOISSON
Prostate
PEACE 1 (GETUG-AFU 21)
A Prospective Randomised Phase III Study of Androgen Deprivation Therapy (+/- Docetaxel) With or Without Local Radiotherapy With or Without Abiraterone Acetate and Prednisone in Patient With Metastatic Hormone-naïve Prostate Cancer.
Paris
FRANCESCO RICCI
Prostate
PEACE 2 (GETUG - AFU 23)
A Randomized Phase III, Factorial Design, of Cabazitaxel and Pelvic Radiotherapy in Patients With Localized Prostate Cancer and High-risk Features of Relapse.
Paris
FRANCESCO RICCI
Appareil pulmonaire
SAFIR 02 Lung
Evaluation of the Efficacy of High Throughput Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Non-small Cell Lung Cancer (Intergroup Trial UNICANCER UC 0105-1305/ IFCT 1301: SAFIR02_Lung)
Paris
CATHERINE DANIEL